ClinConnect ClinConnect Logo
Search / Trial NCT06445023

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

Launched by CELLDEX THERAPEUTICS · May 31, 2024

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Cdx 0159 Barzolvolimab Chronic Spontaneous Urticaria Csu Urticaria Activity Score Itch Severity Score Hives Severity Score

ClinConnect Summary

This clinical trial is studying a new treatment called barzolvolimab for adults with chronic spontaneous urticaria (CSU), a condition that causes itchy hives that can last for a long time. The goal of the study is to find out if barzolvolimab is effective and safe for people who have not found relief from their symptoms using standard allergy medications called non-sedating antihistamines. The trial will compare the effects of barzolvolimab to a placebo, which is an inactive treatment, to see how well it works.

To be eligible for this study, participants must be at least 18 years old and have been diagnosed with CSU for at least six months, even after using antihistamines for at least four weeks. They must also have had significant symptoms in the week leading up to the study. Both men and women can join, but those who are pregnant or breastfeeding cannot. Participants will keep a daily diary of their symptoms and attend regular study visits. This trial offers a chance to access a new treatment option for those struggling with CSU. Your doctor will go over all the details to ensure you meet the criteria for participation.

Gender

ALL

Eligibility criteria

  • Key Inclusion Criteria:
  • 1. Males and females, \>/= 18 years of age.
  • 2. Chronic spontaneous urticaria (CSU) \>/= 6 months prior to Screening (Visit 1).
  • 3. CSU despite the use of a stable regimen of second generation non-sedating H1-antihistamine as defined by:
  • 1. The presence of hives for \>/= 6 weeks at any time prior to Visit 1 despite the use of non-sedating H1-antihistamines.
  • 2. Must be on a stable regimen of second generation non-sedating H1-antihistamine for \>/= 4 weeks prior to study treatment.
  • 3. UAS7 of \>/= 16 and ISS7 of \>/= 8 during the 7 days prior to study treatment.
  • 4. Normal blood counts and liver function tests.
  • 5. Both males and females of child-bearing potential must agree to use highly effective contraceptives during the study and for 150 days after treatment.
  • 6. Willing and able to complete a daily symptom electronic diary and comply with study visits.
  • 7. Participants with and without prior biologic experience are eligible.
  • Key Exclusion Criteria:
  • 1. Women who are pregnant or nursing.
  • 2. Chronic urticaria whose predominant manifestation is due to CIndU.
  • 3. Other diseases associated with urticaria.
  • 4. Active pruritic skin condition in addition to CSU.
  • 5. Medical condition that would cause additional risk or interfere with study procedures.
  • 6. Known HIV, hepatitis B or hepatitis C infection.
  • 7. Vaccination of a live vaccine within 30 days prior to Screening (Visit 1) (subjects must agree to avoid live vaccinations during the study). Inactivated vaccines are allowed such as seasonal influenza injection or authorized COVID-19 vaccine.
  • 8. History of anaphylaxis.
  • 9. Prior treatment with barzolvolimab.
  • There are additional criteria that your study doctor will review with you to confirm you are eligible for the study.

About Celldex Therapeutics

Celldex Therapeutics is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of cancer and other serious diseases. With a strong focus on immuno-oncology, Celldex harnesses the power of the immune system to create targeted therapies designed to improve patient outcomes. The company's robust pipeline includes a range of novel monoclonal antibodies and antibody-drug conjugates, aimed at addressing unmet medical needs in oncology. Committed to advancing scientific research and clinical development, Celldex Therapeutics collaborates with healthcare professionals and regulatory agencies to bring transformative treatments to patients.

Locations

Gent, , Belgium

Madrid, , Spain

San Diego, California, United States

Baltimore, Maryland, United States

Taichung, , Taiwan

Wheaton, Maryland, United States

Los Angeles, California, United States

Hellerup, , Denmark

Seoul, , Korea, Republic Of

Seoul, , Korea, Republic Of

Missoula, Montana, United States

Barcelona, , Spain

Copenhagen Nv, , Denmark

Wheat Ridge, Colorado, United States

Kaohsiung, , Taiwan

Bloemfontein, Free State, South Africa

Brussels, , Belgium

Seongnam Si, , Korea, Republic Of

New York, New York, United States

Toledo, Ohio, United States

München, , Germany

Paris, , France

Kuala Lumpur, , Malaysia

Aarhus N, , Denmark

Ansan, , Korea, Republic Of

Taipei City, , Taiwan

Taipei City, , Taiwan

Kuching, , Malaysia

Miami, Florida, United States

Spokane, Washington, United States

Taoyuan, , Taiwan

Sarasota, Florida, United States

Leuven, Vlaams Brabant, Belgium

George Town, , Malaysia

Johor Bahru, , Malaysia

Kiel, Schleswig Holstein, Germany

Hialeah, Florida, United States

Salamanca, , Spain

Kaohsiung, , Taiwan

Athens, , Greece

Seongnam Si, , Korea, Republic Of

Sofia, , Bulgaria

Fairborn, Ohio, United States

Richmond Hill, Ontario, Canada

San Diego, California, United States

Rockville, Maryland, United States

New Taipei City, , Taiwan

Bexley, Ohio, United States

Córdoba, , Spain

Praha 1, , Czechia

Langenau, , Germany

Hsinchu, , Taiwan

Birmingham, Alabama, United States

Redwood City, California, United States

Markham, Ontario, Canada

San Miguel De Tucuman, Tucuman, Argentina

Auburn Hills, Michigan, United States

Margate, Florida, United States

Athens, , Greece

Tampa, Florida, United States

Waco, Texas, United States

Warsaw, , Poland

Vereeniging, Gauteng, South Africa

Cincinnati, Ohio, United States

Suwon Si, , Korea, Republic Of

Benoni, Gauteng, South Africa

Pretoria, Gauteng, South Africa

Owensboro, Kentucky, United States

Mayfield Heights, Ohio, United States

Toruń, , Poland

Alicante, , Spain

Krugersdorp, Gauteng, South Africa

Maldegem, , Belgium

Milano, , Italy

Katowice, , Poland

Lisboa, , Portugal

Portland, Oregon, United States

Sofia, , Bulgaria

Fountain Valley, California, United States

Upland, California, United States

Saint Petersburg, Florida, United States

Findlay, Ohio, United States

Toronto, Ontario, Canada

Dülmen, Nordrhein Westfalen, Germany

Braga, , Portugal

Skokie, Illinois, United States

Oxnard, California, United States

Indianapolis, Indiana, United States

Metairie, Louisiana, United States

North Charleston, South Carolina, United States

Dallas, Texas, United States

Clarksville, Indiana, United States

Clackamas, Oregon, United States

Plano, Texas, United States

Kielce, , Poland

Louisville, Kentucky, United States

Coral Gables, Florida, United States

Miami, Florida, United States

Ann Arbor, Michigan, United States

Ypsilanti, Michigan, United States

Cortland, New York, United States

Oklahoma City, Oklahoma, United States

Ipoh, , Malaysia

Scottsdale, Arizona, United States

Lee's Summit, Missouri, United States

Cortland, New York, United States

Philadelphia, Pennsylvania, United States

Sofia, , Bulgaria

Boynton Beach, Florida, United States

Saint Joseph, Missouri, United States

Razgrad, , Bulgaria

Stara Zagora, , Bulgaria

Praha 6, , Czechia

Langenau, Baden Württemberg, Germany

Kiel, Schleswig Holstein, Germany

Thessaloníki, , Greece

Katowice, , Poland

Szczecin, , Poland

Warsaw, , Poland

Wrocław, , Poland

Wrocław, , Poland

łódź, , Poland

Madrid, , Spain

Villareal, , Spain

Lisboa, , Portugal

Toronto, Ontario, Canada

Pretoria, Gauteng, South Africa

Ocean City, New Jersey, United States

Buenos Aires, , Argentina

Caba, Ciudad Autonoma De Buenos Aires, Argentina

Caba, Ciudad Autonoma De Buenos Aires, Argentina

Caba, Ciudad Autonoma De Buenos Aires, Argentina

Rosario, Sante Fe, Argentina

Rosario, Sante Fe, Argentina

Rosario, Sante Fe, Argentina

San Miguel De Tucuman, Tucuman, Argentina

San Miguel De Tucuman, Tucuman, Argentina

Brussels, , Belgium

Haskovo, , Bulgaria

Sofia, , Bulgaria

Sofia, , Bulgaria

Yambol, , Bulgaria

Praha 8, , Czechia

Nantes, , France

Nice, , France

Löhne, Niedersachsen, Germany

Bonn, Nordrhein Westfalen, Germany

Attikí, , Greece

Ancona, , Italy

Mantova, , Italy

Torino, , Italy

Verona, , Italy

Bialystok, , Poland

Bydgoszcz, , Poland

Kraków, , Poland

Poznan, , Poland

Skarzysko Kamienna, , Poland

Wroclaw, , Poland

Wroclaw, , Poland

Wrocław, , Poland

Newtown, Gauteng, South Africa

Raslouw, Gauteng, South Africa

Durban, Kwa Zulu Natal, South Africa

Mowbray, Western Cape, South Africa

Buenos Aires, , Argentina

Lobos, , Argentina

Buenos Aires, Caba, Argentina

Rosario, Sante Fe, Argentina

Edegem, Antwerpen, Belgium

Plovdiv, , Bulgaria

Sofia, , Bulgaria

Hamilton, Ontario, Canada

Praha 10, , Czechia

Pierre Benite, Rhone, France

La Tronche, , France

Darmstadt, Hesse, Germany

Bramsche, , Germany

Mainz, , Germany

Seongdong, Seoul Teugbyesolsi, Korea, Republic Of

Białystok, , Poland

Gdańsk, , Poland

Poznań, , Poland

Warszawa, , Poland

Aveiro, , Portugal

Coimbra, , Portugal

Matosinhos, , Portugal

Porto, , Portugal

Setúbal, , Portugal

Pretoria, , South Africa

Sabadell, Barcelona, Spain

Taichung City, , Taiwan

Taipei City, , Taiwan

Murray, Utah, United States

Buenos Aires, , Argentina

Brussels, , Belgium

Edmonton, Alberta, Canada

St. John's, Newfoundland And Labrador, Canada

Rouen, , France

Elbląg, , Poland

Vila Nova De Gaia, , Portugal

Buenos Aires, Buenos Aires Province, Argentina

Buenos Aires, Buenos Aires Province, Argentina

Lobos, Buenos Aires Province, Argentina

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported